Ono Pharma licenses Biohaven IgG degrader portfolio for Japan, South Korea, Taiwan, ASEAN in deal worth up to USD 100 million

Bitget2026/10/08 08:02

ONO Pharma signed an exclusive license with Biohaven to develop, register, and sell IgG degrader drugs across Japan, South Korea, Taiwan, and ASEAN. Deal covers Biohaven’s MoDE-based IgG degrader portfolio, led by BHV-1300, now in global Phase 3 trials for Graves’ disease. Biohaven to receive USD 80 million upfront, USD 20 million in milestones, and about 20% royalties on net sales. ONO Pharma expects a minor impact on consolidated results for the fiscal year ending March 31, 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail

Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

智通财经•2026/11/09 07:32

Canaccord Genuity: Lowers Oklo's target price to $66

格隆汇•2026/11/09 07:01

Bernstein: Huang Renxun's Controversy May Increase Nvidia's Regulatory Risks, but Maintains $400 Price Target

Cointime•2026/11/09 06:43

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41